Did you read the article about Rituximab?

Anonymous's picture

A collaboration of Miller School physicians, surgeons and scientists has unlocked the mechanism of a drug used to prevent recurrent kidney disease. The finding, which has implications for the diagnosis and treatment of many other diseases, involves the action of rituximab, a B-cell lymphoma therapy, in treating recurrent Focal Segmental Glomerulosclerosis (FSGS) in children and young adults.

The finding is published in the June 1 edition of the journal Science Translational Medicine. Alessia Fornoni, M.D., Ph.D., assistant professor of medicine in the Division of Nephrology and Hypertension, is the lead author of the study, which not only shows that rituximab is a valid treatment strategy in preventing recurrent FSGS in kidney transplant patients, but also for the first time uncovers a previously unknown mechanism of action of rituximab.

"Thanks to the families of The NephCure Foundation and in particular Allie Genatt for inspiring new ideas for treatment of FSGS," said Dr. Fornoni in the study's acknowledgements.

Read More

 

Miriam
mlong@nephcure.org
1.866 NephCure (637.4287) ext. 10

Customize This